Literature DB >> 24815848

Hypermethylation of p15 gene in diffuse - large B-cell lymphoma: association with less aggressiveness of the disease.

Milena Krajnović1, Maja Peruničić Jovanović, Biljana Mihaljević, Boško Anđelić, Olivera Tarabar, Slavica Knežević-Ušaj, Koviljka Krtolica.   

Abstract

In this study, methylation-specific polymerase chain reaction was used to investigate the potential prognostic significance of the methylation status of p15, p16, MGMT, and DAPK genes in 51 specimens of diffuse large B-cell lymphoma (DLBCL). Hypermethylation of p15 gene was significantly more prevalent in patients without relapse (p = 0.001) and there was a trend toward more frequent presence of p15 methylation in patients without death outcome within 5-year follow-up period (p = 0.086) Also, there was a trend toward accumulation of p15 methylation with favorable clinicopathological parameters including: age ≤ 60 years (p = 0.091), normal levels of lactate dehydrogenase (p = 0.090), Eastern Cooperative Oncology Group performance status < 2 (p = 0.095), and low/intermediate low International Prognostic Index (p = 0.076). In the female group and group of the patients without bulky tumor mass, treated with chemotherapeutic regimens including rituximab, methylation of p15 was significantly related to longer overall survival (p = 0.036 and 0.027, respectively). Our results suggest that promoter methylation of p15 gene could have prognostic value in DLBCL patients treated with rituximab when used in combination with gender and tumor size.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  diffuse large B-cell lymphoma; methylation; p15; prognosis; rituximab

Mesh:

Substances:

Year:  2014        PMID: 24815848      PMCID: PMC5350871          DOI: 10.1111/cts.12162

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  41 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27.

Authors:  M Sánchez-Beato; A I Sáez; I C Navas; P Algara; M Sol Mateo; R Villuendas; F Camacho; A Sánchez-Aguilera; E Sánchez; M A Piris
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia.

Authors:  S Deneberg; M Grövdal; M Karimi; M Jansson; H Nahi; A Corbacioglu; V Gaidzik; K Döhner; C Paul; T J Ekström; E Hellström-Lindberg; S Lehmann
Journal:  Leukemia       Date:  2010-03-18       Impact factor: 11.528

4.  Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma.

Authors:  Manel Esteller; Gianluca Gaidano; Steven N Goodman; Vittorina Zagonel; Daniela Capello; Barbara Botto; Davide Rossi; Annunziata Gloghini; Umberto Vitolo; Antonino Carbone; Stephen B Baylin; James G Herman
Journal:  J Natl Cancer Inst       Date:  2002-01-02       Impact factor: 13.506

Review 5.  Repair of O(6)-alkylguanine by alkyltransferases.

Authors:  A E Pegg
Journal:  Mutat Res       Date:  2000-04       Impact factor: 2.433

Review 6.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

7.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

8.  Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas.

Authors:  K Amara; M Trimeche; S Ziadi; A Laatiri; M Hachana; S Korbi
Journal:  Ann Oncol       Date:  2008-06-06       Impact factor: 32.976

9.  p15 promoter methylation - a novel prognostic marker in glioblastoma patients.

Authors:  Silke Wemmert; Marc Bettscheider; Simone Alt; Ralf Ketter; Kai Kammers; Wolfgang Feiden; Wolf-Ingo Steudel; Jörg Rahnenführer; Steffi Urbschat
Journal:  Int J Oncol       Date:  2009-06       Impact factor: 5.650

10.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

View more
  4 in total

1.  DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.

Authors:  Alberto J Arribas; Andrea Rinaldi; Afua A Mensah; Ivo Kwee; Luciano Cascione; Eloy F Robles; Jose A Martinez-Climent; David Oscier; Luca Arcaini; Luca Baldini; Roberto Marasca; Catherine Thieblemont; Josette Briere; Francesco Forconi; Alberto Zamò; Massimiliano Bonifacio; Manuela Mollejo; Fabio Facchetti; Stephan Dirnhofer; Maurilio Ponzoni; Govind Bhagat; Miguel A Piris; Gianluca Gaidano; Emanuele Zucca; Davide Rossi; Francesco Bertoni
Journal:  Blood       Date:  2015-01-22       Impact factor: 22.113

Review 2.  Site-Specific DNA Demethylation as a Potential Target for Cancer Epigenetic Therapy.

Authors:  Sultan Abda Neja
Journal:  Epigenet Insights       Date:  2020-10-21

3.  Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma.

Authors:  Lasse Sommer Kristensen; Fazila Asmar; Konstantinos Dimopoulos; Mette Kathrine Nygaard; Derya Aslan; Jakob Werner Hansen; Elisabeth Ralfkiaer; Kirsten Grønbæk
Journal:  Oncotarget       Date:  2014-10-30

4.  Prognostic significance of DAPK promoter methylation in lymphoma: A meta-analysis.

Authors:  Hong Wang; Lin-Yu Zhou; Ze-Bing Guan; Wen-Bin Zeng; Lan-Lan Zhou; Ya-Nan Liu; Xue-Yi Pan
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.